{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:47:48Z","timestamp":1791020868396,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T00:00:00Z","timestamp":1340064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0038273","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T21:07:47Z","timestamp":1340140067000},"page":"e38273","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"isrctn27354239","registry":"10.18810\/isrctn"}],"author":[{"given":"Genevi\u00e8ve","family":"Derumeaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ernande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Serusclat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Servan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Picandet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Gavini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf the REGULATE trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/diacare.29.03.06.dc05-1439","article-title":"Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study.","volume":"29","author":"P Moulin","year":"2006","journal-title":"Diabetes Care 2006"},{"key":"ref2","first-page":"2941","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.","volume":"108","author":"RW Nesto","year":"2003","journal-title":"Circulation 2003"},{"key":"ref3","first-page":"215","article-title":"[Valvular heart disease associated with benfluorex].","volume":"56","author":"RJ Rafel","year":"2003","journal-title":"Rev Esp Cardiol 2003"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2006.00441.x","article-title":"Valvular heart disease in a patient taking benfluorex.","volume":"20","author":"P Noize","year":"2006","journal-title":"Fundam Clin Pharmacol 2006"},{"key":"ref5","article-title":"Screening for benfluorex and its major urinary metabolites in routine doping controls.","author":"M Thevis","year":"2010"},{"key":"ref6","first-page":"254","article-title":"Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein.","volume":"335","author":"K Seuwen","year":"1988","journal-title":"Nature 1988"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1183\/09031936.00086308","article-title":"Fenfluramine-like cardiovascular side-effects of benfluorex.","volume":"33","author":"K Boutet","year":"2009","journal-title":"Eur Respir J 2009"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e10128","DOI":"10.1371\/journal.pone.0010128","article-title":"Benfluorex and unexplained valvular heart disease: a case-control study.","volume":"5","author":"I Frachon","year":"2010","journal-title":"PLoS ONE 2010"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.","volume":"19","author":"A Weill","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf 2010"},{"key":"ref10","article-title":"National Pharmacovigilance Committee meeting of Tuesday 29 September 2009.","year":"2009"},{"key":"ref11","first-page":"39","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"R Zanettini","year":"2007","journal-title":"N Engl J Med 2007"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.","volume":"16","author":"WA Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr 2003"},{"key":"ref13","first-page":"725","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.","volume":"339","author":"NJ Weissman","year":"1998","journal-title":"N Engl J Med 1998"},{"key":"ref14","first-page":"1179","article-title":"Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease.","volume":"363","author":"G Van Camp","year":"2004","journal-title":"Lancet 2004"},{"key":"ref15","first-page":"34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.","volume":"6","author":"CF Dahl","year":"2008","journal-title":"BMC Med 2008"},{"key":"ref16","first-page":"2071","article-title":"Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.","volume":"101","author":"JG Jollis","year":"2000","journal-title":"Circulation 2000"},{"key":"ref17","first-page":"577","article-title":"Drug-induced fibrotic valvular heart disease.","volume":"374","author":"S Bhattacharyya","year":"2009","journal-title":"Lancet 2009"},{"key":"ref18","first-page":"6","article-title":"Drugs and valvular heart disease.","volume":"356","author":"BL Roth","year":"2007","journal-title":"N Engl J Med 2007"},{"key":"ref19","first-page":"2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.","volume":"102","author":"RB Rothman","year":"2000","journal-title":"Circulation 2000"},{"key":"ref20","first-page":"581","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"HM Connolly","year":"1997","journal-title":"N Engl J Med 1997"},{"key":"ref21","first-page":"1517","article-title":"Long-term serotonin administration induces heart valve disease in rats.","volume":"111","author":"BI Gustafsson","year":"2005","journal-title":"Circulation 2005"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice.","volume":"113","author":"A Mekontso-Dessap","year":"2006","journal-title":"Circulation 2006"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(99)00896-6","article-title":"Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.","author":"RB Rothman","year":"2000"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"H1940","DOI":"10.1152\/ajpheart.01177.2008","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.","volume":"296","author":"S Droogmans","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol 2009"},{"key":"ref25","first-page":"75","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.","volume":"57","author":"LW Fitzgerald","year":"2000","journal-title":"Mol Pharmacol 2000"},{"key":"ref26","first-page":"1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \u00ab Ecstasy \u00bb) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.","volume":"63","author":"V Setola","year":"2003","journal-title":"Mol Pharmacol 2003"},{"key":"ref27","first-page":"710","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.","volume":"76","author":"X-P Huang","year":"2009","journal-title":"Mol Pharmacol 2009"},{"key":"ref28","first-page":"902","article-title":"Functional consequence of serotonin\/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure?","volume":"108","author":"CG Nebigil","year":"2003","journal-title":"Circulation 2003"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/CIRCULATIONAHA.105.593459","article-title":"Serotonin transporter mechanisms and cardiac disease.","volume":"113","author":"RJ Levy","year":"2006","journal-title":"Circulation 2006"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0038273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:00:38Z","timestamp":1642564838000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0038273"}},"subtitle":[],"editor":[{"given":"James M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,19]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0038273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,19]]}}}